Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 13, 2014. The report details the announcement of clinical trial results for darapladib, an investigational Lp-PLA2 inhibitor intended for the treatment of atherosclerosis and acute coronary syndrome.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial outcomes and does not contain financial statements.
Material Changes and Clinical Outcomes
- Primary Endpoint Failure: The SOLID-TIMI 52 phase III study failed to meet its primary endpoint. Darapladib did not achieve a statistically significant reduction in major coronary events compared to placebo when added to standard of care in patients following an acute coronary syndrome.
- Consistency with Prior Data: The safety profile of darapladib showed no major concerns and was consistent with the previously reported STABILITY phase III study (announced November 2013), which also failed to meet its primary endpoint in patients with chronic coronary heart disease.
- Regulatory Impact: The outcome does not support a regulatory submission for darapladib in atherosclerosis. The drug is not approved for use anywhere in the world.
Management Commentary and Outlook
Patrick Vallance, GSK's President of Pharmaceuticals R&D, expressed disappointment regarding the study outcome. Management confirmed that the phase III program for darapladib will not proceed to regulatory submission based on these results. GSK stated it will continue to analyze the data to better understand the findings. The company acknowledged the participation of over 30,000 patients across its two phase III studies.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the company's 2013 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the impact of the darapladib trial failure on GSK's R&D pipeline valuation and future cardiovascular drug strategy.
- Review the full data analysis of the SOLID-TIMI 52 study once presented at the upcoming scientific meeting.
- Assess potential write-offs or adjustments to R&D expenses related to the discontinued darapladib program in upcoming financial reports.
- Confirm the status of other cardiovascular assets in GSK's portfolio given the failure of two major phase III studies for this drug candidate.